{"id":995081,"date":"2026-08-13T16:05:26","date_gmt":"2026-08-13T20:05:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-outlines-strategic-priorities-including-a-focused-commercial-strategy-and-reports-second-quarter-2026-financial-results\/"},"modified":"2026-08-13T16:05:26","modified_gmt":"2026-08-13T20:05:26","slug":"ars-pharmaceuticals-outlines-strategic-priorities-including-a-focused-commercial-strategy-and-reports-second-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ars-pharmaceuticals-outlines-strategic-priorities-including-a-focused-commercial-strategy-and-reports-second-quarter-2026-financial-results\/","title":{"rendered":"ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results"},"content":{"rendered":"
\n

\n $26.2 million in U.S.\u00a0<\/em>
\n
\n neffy<\/em>
\n <\/strong>
\n \u00ae net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts <\/em>\n <\/p>\n

\n Commercial investment realigned toward targeted provider engagement, significantly reducing total operating expenses for 2H 2026 and supporting an expected path to cash flow breakeven by the end of 2027<\/em>\n <\/p>\n

\n Commercial operations strengthened with appointment of Meg Smith as Chief Commercial Officer and completed expansion of field sales organization<\/em>\n <\/p>\n

\n Interim data from Phase 2b trial in chronic spontaneous urticaria (CSU) expected in Q1 2027; no FDA-approved on-demand treatment currently exists for acute CSU flares<\/em>\n <\/p>\n

\n Conference call to be held today, August 13, 2026, at 1:30 p.m. PT \/ 4:30 p.m. ET<\/em>\n <\/p>\n

SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect against allergic reactions that could lead to anaphylaxis, today outlined the strategic priorities and operating framework that will guide the Company going forward, its refined commercial strategy for\u00a0neffy<\/em><\/strong>\u00ae (epinephrine nasal spray), and its financial results for the second quarter ended June 30, 2026.<\/p>\n

\u201cIt is a privilege to lead ARS Pharma at this pivotal time, and my conviction in the opportunity ahead has only grown since stepping into this role. As the first and only needle-free epinephrine option, neffy<\/em><\/strong> is well positioned to become the standard of care for patients and caregivers in this multi-billion-dollar market,\u201d said Donn Casale, President and CEO of ARS Pharma. \u201cToday, we are announcing a shift in focus to provider adoption, with a more efficient commercial strategy intended to drive market share growth without sacrificing revenue. We believe that provider awareness and recommendation will be the cornerstone to growing the neffy<\/em><\/strong> brand. Our confidence in continued revenue growth, along with a more efficient commercial model, is expected to provide the foundation for long-term value creation. Beyond neffy<\/em><\/strong>, advancing our intranasal epinephrine platform into CSU unlocks a potential major growth opportunity in an area of high unmet need built on top of our existing commercial infrastructure.\u201d<\/p>\n

\n Updated Strategic Priorities<\/strong>\n <\/p>\n

Following a comprehensive assessment of ARS Pharma\u2019s commercial, clinical, and business operations, the Company has established a core set of strategic priorities intended to drive continued value creation from neffy<\/em><\/strong> and the intranasal epinephrine platform:<\/p>\n

    \n
  1. \n Targeted commercial execution. <\/strong>ARS Pharma is shifting its focus from broad consumer-directed marketing to targeted engagement with high-volume prescribers, a strategy that has already demonstrated to grow field-targeted market share.<\/li>\n
  2. \n Financial discipline aligned with <\/strong>
    \n
    \n neffy<\/em>
    \n <\/strong>
    \n adoption rate. <\/strong>ARS Pharma has implemented a rigorous cost optimization framework, significantly reducing its SG&A expense, that focuses on building a profitable neffy<\/em><\/strong> franchise to drive shareholder value and provide financial support for platform expansion.<\/li>\n
  3. \n Advance CSU clinical program. <\/strong>ARS Pharma is extending its intranasal epinephrine platform into CSU. With no FDA-approved, on-demand options currently available to manage acute flares, the Company\u2019s intranasal epinephrine platform may address a critical unmet need in CSU and offer a compelling market expansion opportunity.<\/li>\n<\/ol>\n

    \n Commercial Leadership and a Fully Deployed Field Organization<\/strong>\n <\/p>\n

    ARS Pharma today announced the appointment of Meg Smith as Chief Commercial Officer, effective August 17, 2026. Ms. Smith is a commercial executive with more than 25 years of progressive leadership experience. Most recently, she led the commercial organization at Dynavax Technologies that successfully launched HEPLISAV-B\u00ae.<\/p>\n

    \u201cneffy<\/em><\/strong> is well positioned to become the new standard of care in a large, underserved market,\u201d said Ms. Smith. \u201cThere is a solid foundation in place, growing prescriber momentum, and a talented field organization. I am excited to join the commercial leadership team at ARS where we will be relentlessly focused on provider-centered execution to convert that foundation into durable market share growth.\u201d<\/p>\n

    ARS Pharma also announced that the expansion of its field sales organization is now complete. Sales force efforts will focus primarily on the highest-value prescribers, which represent 44% of the total U.S. market opportunity.<\/p>\n

    Mr. Casale added, \u201cExecuting our enhanced commercial strategy requires having the right leadership and footprint, and I am incredibly pleased to welcome Meg to the team. I am confident that she has the right capabilities and experience to drive this next chapter of the neffy<\/em><\/strong> launch, having seen her ability to inspire teams and drive operational rigor firsthand. The impact of our sales force is clear, and where we actively call on accounts, our share is meaningfully larger than our total market share. I am excited to see the compounding impact of a fully deployed, focused sales team under Meg\u2019s leadership.\u201d<\/p>\n

    \n
    \n neffy<\/em>
    \n <\/strong> U.S. commercial metrics as of the end of the second quarter of 2026 include:<\/p>\n